Vaccines for Emerging Infectious Diseases

Vaccines for emerging infectious diseases: The rapid spread presents new hurdles for vaccine development, regulation, and distribution. While speed is crucial, ensuring safety, monitoring for variants, and equitable access are equally important.

Vaccines for Emerging Infectious Diseases Overview

• Factors like population growth, urbanization, and travel contribute to the spread of infectious diseases.
• The COVID-19 pandemic, caused by the SARS-CoV-2 virus,  had a significant impact worldwide, leading to millions of infections and deaths.
• Vaccines offer the best hope for controlling pandemics like COVID-19.
• This highlights the need for better surveillance, management, and global cooperation to control future disease threats.

Emerging and Reemerging Infectious Diseases

• Yellow Fever: A disease spread by mosquitoes, common in Africa and South America. There have been outbreaks in countries like Angola, Congo, Nigeria, and Brazil. There are vaccines available, but there have been concerns about having enough supply.
• Dengue: Another mosquito-borne disease that is spreading in many countries. Around 400 million people get dengue each year, with up to 22,000 deaths. One vaccine, Dengvaxia, is licensed in many countries but not widely used due to safety concerns.
• Cholera: A bacterial disease causing severe diarrhea, often in Asia and Africa. Antibiotic resistance is growing, making treatment more challenging. Vaccines are available and used during outbreaks.
• Typhoid fever: A severe bacterial disease with more drug-resistant strains, especially in Pakistan and India. New vaccines are being developed to fight these resistant strains.

Quick COVID-19 Vaccine Development: Key Factors

• New Technologies: mRNA, viral vector technologies, and recombinant protein approaches were important in quick vaccine development.
• Helpful in  Other Diseases: These new vaccine platforms may also benefit diseases like HIV, malaria, and tuberculosis (TB), although success isn't guaranteed.
• Funding and Support: Funding accelerated vaccine development, allowing for simultaneous preclinical studies, trials, and manufacturing.
• Future Investments: Increased funding for neglected and emerging diseases could bring significant global health benefits.
• Governance Innovations: Initiatives like the Coalition for Epidemic Preparedness Innovations (CEPI) helped pivot efforts towards COVID-19 vaccines and could be done the same for other diseases.
• Global Distribution: Lessons learned from COVID-19 vaccine distribution highlight the need for equal allocation systems based on principles of fairness and justice.

Different Types of Vaccines for Treating Emerging Infectious Diseases

Challenges Faced During Vaccine Development

• Studies comparing immune responses could replace endpoint trials.
• Finding immune protection clues is tough.
• Trials might not fully show how vaccines benefit whole populations.
• Future trials might focus on vaccine effectiveness and group protection.
• Whether trials will use clinical endpoints or immune responses is uncertain.
• It's hard to find immune clues, especially with highly effective vaccines.
• Safety and risks like enhanced respiratory disease need careful study.

Strategies to Expedite Vaccine Availability and Distribution

• Vaccine nationalism and bilateral agreements between high-income countries and manufacturers can impact initial vaccine access.
• The Developing Countries Vaccine Manufacturers Network (DCVMN) aims to increase the availability and affordability of vaccines, with its members supplying a large portion of global vaccine needs.
• Technology transfers to DCVMN members have contributed significantly to global health, such as the oral cholera vaccine.
• For COVID-19 vaccines, many companies have licensed production to other manufacturers worldwide.
• Practical aspects like supply, dosing, and storage need optimization for more comprehensive vaccine implementation.
• Some vaccines require ultracold storage because of scalability challenges, while research is ongoing to assess the effectiveness of single doses.